Adagio Therapeutics Appoints Senior Pharmaceutical Industry and Regulatory Executives to Board of Directors
Topic : Personnel
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions to treat infectious diseases with pandmic potential, today announced the expansion of the Board of Directors of the company with key appointments including:
Tom Heyman, Former Chairman of the Johnson & Johnson Development Corporation (JJDC)
Anand Shah, DM, former Deputy Commissioner for Medical and Scientific Affairs at the United States Food and Drug Administration (FDA).
Michael Wyzga, prsident de MSW Consulting, Inc.
I am very happy to welcome Tom, Anand and Mike to our board of directors; They bring us unparalleled expertise gained through their respective roles in the industry, and join us at a critical time as we prepare for the potential commercialization of ADG20 to fight COVID-19, especially rapidly emerging variants. , said Ren Russo, co-founder of Adagio and chairman of the board. During his 37-year career with Johnson & Johnson, Tom has held a wide range of leadership roles in R&D, business development, corporate strategy and capital investment. Deputy Commissioner of the FDA until January 2021, Anand led the development of a consensus medical and scientific policy and, since the COVID-19 pandemic, he has worked in the federal government and collaborated with the private sector to accelerate the development of vaccines and treatments.
Jane Henderson, Chief Financial Officer at Adagio, added: As we accelerate various clinical trials with ADG20, financial strength and discipline are paramount to our success. We are very happy to welcome Mike to our board; he brings us years of experience as director of exceptional financial operations in public and private companies in the pharmaceutical industry. We look forward to partnering with him, as well as Tom and Anand, and benefiting from their invaluable knowledge of clinical development, financial best practices, regulatory strategy, political commitment and business strategy execution. which will allow us to tackle this global pandemic today.
Tom Heyman has extensive experience in the biopharmaceutical industry, particularly in the area of business development and venture capital. He most recently served as chairman of JJDC, the Johnson & Johnson venture capital group, where he managed approximately $ 1.5 billion in capital and oversaw investments in more than 120 companies. Prior to joining JJDC, Mr. Heyman led the business development of Johnson & Johnson’s pharmaceutical group, Janssen for 23 years, participating in hundreds of licensing and M&A negotiations. Under his leadership, major licensing negotiations were carried out for products such as Levaquin, Aciphex, Incivo, Olysio, Velcade, Invokana, Imbruvica, Xarelto and Darzalex, with many of these products reaching sales in excess of $ 1 billion annually. . During his tenure, he also led a major restructuring within Janssen Belgium and implemented a new strategic plan for the site oriented mainly towards external innovation and value creation. Mr. Heyman holds a master’s degree in law from KU Leuven, Belgium. He pursued postgraduate studies in international law in Geneva, Switzerland, and postgraduate studies in business management at the University of Antwerp, Belgium.
Anand Shah, DM, is a health policy leader in the United States; he most recently served as deputy commissioner for medical and scientific affairs at the FDA. Dr Shah has been responsible for developing medical and scientific policy for high priority programs, including advanced manufacturing, coronavirus acceleration program, COVID-19 vaccine development, and testing. decentralized clinics. Under his leadership, the FDA launched the Pandemic Preparedness and Recovery Plan (PREPP) to strengthen the COVID-19 pandemic response and resilience for future public health emergencies. Dr. Shah has represented the FDA to senior policy makers in the White House, Cabinet, Congress, and federal and local state governments. He previously held leadership positions with the Centers for Medicare & Medicaid Services, as Senior Medical Advisor and Chief Medical Officer of the Center for Medicare & Medicaid Innovation. Dr. Shah served as Chief Resident during his residency in Radiation Oncology at Columbia University. He also holds a doctorate in medicine from the University of Pennsylvania and a diploma in management and health care policy from the Harvard School of Public Health. Dr Shah holds a degree in economics from Duke University.
Since 2013, Michael Wyzga has served as President of MSW Consulting, Inc., a private company specializing in strategic biotechnology consulting. Previously, he served as President, CEO and Board Member of Radius Health, Inc. From 1993 to 2011, Mr. Wyzga held various executive positions at Genzyme Corporation, including those of Executive Vice President of Finance and financial director. During his time at Genzyme, Mr. Wyzga played a key role in the successful development and commercialization of many important therapies, including Cerezyme treating Gaucher disease, Fabrazyme treating Fabry disease, Renagel treating of dialyss and Campath patients treating chronic lymphocytic leukemia. Mr. Wyzga has served on the boards of directors of several public companies, including Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc., X4 Pharmaceuticals, GenSight Biologics, LogicBio Therapeutics, Akebia Therapeutics, Inc., Idenix Pharmaceuticals, Inc. and Prosensa Holding BVM Wyzga obtained an MBA from Providence College and a BA from Suffolk University.
About Adagio Therapeutics
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions to treat infectious diseases with pandemic potential. Adagio’s antibody portfolio has been enhanced through the antibody engineering capabilities of industry-leading Adimab, which is designed to provide patients and clinicians with an effective combination of potency, strain, long-lasting protection (e.g. longer half-life), ease of manufacture and affordable price. Adagio’s anti-SARS-CoV-2 antibody portfolio comprises multiple, non-competing broad-spectrum neutralizing antibodies carrying distinct binding pitopes, headed by ADG20. Adagio has secured production capacity for ADG20 from third party contract manufacturers until the end of clinical trials and, if approved by regulatory authorities, until initial commercial launch. For more information, please visit the website www.adagiotx.com.
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the communiqu is that of the communiqu in its original language. The translation must always be compared to the source text, which will set a precedent.
These press releases may also be of interest to you